Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial  Chinedu Nwokoro, MBBChir, Hitesh Pandya, MD, Stephen Turner, MD, Prof Sandra Eldridge, PhD, Prof Christopher J Griffiths, MD, Tom Vulliamy, PhD, Prof David Price, MRCGP, Marek Sanak, PhD, John W Holloway, PhD, Rossa Brugha, BMBCh, Lee Koh, BSC, Iain Dickson, MRes, Clare Rutterford, MSc, Prof Jonathan Grigg, MD  The Lancet Respiratory Medicine  Volume 2, Issue 10, Pages 796-803 (October 2014) DOI: 10.1016/S2213-2600(14)70186-9 Copyright © 2014 Nwokoro et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 1 Trial profile *Perceived inefficacy is on the side of patient. †Data for the primary outcome were obtained from children whose parents responded to at least one follow-up phone call. The Lancet Respiratory Medicine 2014 2, 796-803DOI: (10.1016/S2213-2600(14)70186-9) Copyright © 2014 Nwokoro et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 2 Dot plot of urinary LTE4 by variable numbers of copies of the Sp1-binding motif (either 5/5, 5/x, or x/x, in which x does not equal 5) in the ALOX5 promoter region 11 datapoints were outside the axis and are not shown for convenience. Horizontal bars within plots represent mean. LTE4=leukotriene E4. ALOX5=arachidonate 5-lipoxygenase. The Lancet Respiratory Medicine 2014 2, 796-803DOI: (10.1016/S2213-2600(14)70186-9) Copyright © 2014 Nwokoro et al. Open Access article distributed under the terms of CC BY Terms and Conditions